All In Biotech

Drug Trial Radar · NCT02837692

A Study to Assess the Effects of Age and Gender on the Pharmacokinetics of JNJ-42847922 in Healthy Adults

An Open-Label Single Dose Study to Assess the Effects of Age and Gender on the Pharmacokinetics of JNJ-42847922 in Healthy Adults

Last checked: Nov 20, 2026Latest source record: Oct 30, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

140

Actual

Start

Jun 8, 2016

Primary completion

Sep 7, 2017

Study completion Sep 11, 2017

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jul 19, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the pharmacokinetics of single-dose evening administration of JNJ-42847922 in elderly non-Asian adults compared with weight- and gender-matched young healthy non-Asian adults and to assess the pharmacokinetics of single-dose evening administration of JNJ-42847922 in healthy Japanese adults.

Conditions

  • Healthy

Interventions

  • JNJ-42847922 10 milligram (mg)Drug

    JNJ-42847922 will be administered as single tablet of 10 mg, orally, once on Day 1.

  • JNJ-42847922 20 mgDrug

    JNJ-42847922 will be administered as 1 tablet of 20 mg, orally, once on Day 1.

  • JNJ-42847922 40 mgDrug

    JNJ-42847922 will be administered as 2 tablets of 20 mg, orally, once on Day 1.

  • JNJ-42847922 60 or 80 mgDrug

    JNJ-42847922 will be administered as 3 or 4 tablets of 20 mg, orally, once on Day 1. Dose to be determined from Cohort 3, Period 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Plasma Concentration (Cmax) of JNJ-42847922Time frame: Day 1 (Pre-dose) up to Day 3
  2. Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-last]) of JNJ-42847922Time frame: Day 1 (Pre-dose) up to Day 3
  3. Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC [0-infinity]) of JNJ-42847922Time frame: Day 1 (Pre-dose) up to Day 3

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Cypress, California

  • Site not named

    Knoxville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.